GT Biopharma Inc GTBP 深 滬
等待開盤 06-03 09:30:00 美东时间
0.4672
+0.025
+5.70%
華盛通- 最 高0.4741
- 今 開0.4516
- 成交量 218.99万股
- 最 低 0.4224
- 昨 收 0.442
- 總市值 1684.86万
- 52周最高 3.85
- 市盈率 靜 --
- 換手率 6.07%
- 52周最低 0.261
- 委 比 87.65%
- 總股本 3606.29万
- 歷史最高 591.99
- 量 比 1.06
- 振 幅 11.70%
- 歷史最低 0.261
- 每 手 1
- 風險率 0.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout
GT Biopharma says AI-driven drug discovery tools are accelerating pipeline development and may yield new pre-IND candidates by 2027.
06-01 19:31
Nasdaq Grants GT Biopharma Additional 180 Days To Regain Compliance
https://www.sec.gov/ix?doc=/Archives/edgar/data/109657/000149315226024913/form8-k.htm
05-22 20:11
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
Issued on behalf of GT Biopharma, Inc. SAN FRANCISCO, May 18, 2026 /PRNewswire/ -- USA News Group News Commentary — For more than two decades, B7-H3 sat on the shortlist of theoretically pe...
05-19 02:22
GT Biopharma Q1 EPS $(0.11) Misses $(0.08) Estimate
GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.08) by 37.5 percent. This is a 66.67 percent increase over losses of $(0.33) per share from the
05-15 20:19
GT Biopharma Reports First Quarter 2026 Financial Results
GT Biopharma announced its Q1 2026 financial results, highlighting $9 million in cash and ongoing Phase 1 trials for GTB-3650 and GTB-5550. GTB-3650 targets CD33-positive leukemias, with enrollment progressing through dose escalation cohorts. GTB-5550, the first subcutaneously administered TriKE, focuses on B7-H3-positive solid tumors, with enrollment ongoing across multiple tumor types. The company expects updates on both programs in H2 2026. GT...
05-15 12:00
EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types
GT Biopharma doses first patient in Phase 1 GTB-5550 trial targeting B7-H3-positive solid tumors with subcutaneous TriKE therapy.
05-14 20:16
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Alpha Compute (NASDAQ:ALP) shares increased by 71.3% to $0.46 during T...
05-14 20:05
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Intellia Therapeutics (NASDAQ:NTLA) stock rose 19.1% to $16.23 during ...
04-25 05:05
GT Biopharma to Participate in the 38th Annual Roth Conference
GT Biopharma, Inc. (NASDAQ: GTBP) announced that its Executive Chairman and CEO, Michael Breen, will participate in the 38th Annual Roth Conference on March 22-24, 2026, in Laguna Niguel, CA. The Company will present on March 24, 2026, at 1:30 PM PDT and will be available for one-on-one investor meetings. For more information, visit https://www.gtbiopharma.com. The Company focuses on immuno-oncology therapeutics using its proprietary TriKE® NK ce...
03-11 11:00
GT Biopharma reports FY results
GT Biopharma press release (GTBP): FY The Company reported a net loss of approximately $28.4 million for the year ended December 31, 2025, compared to $13.2 million for the prior year. The Company re...
03-03 03:42
